BMJ Open
Does completion of radical hysterectomy improve oncological outcomes of women with clinical early-stage cervical cancer and intraoperative detection of nodal involvement?: protocol for a systematic review and meta-analysis

Cui Hu,1 Yu Xu,2 Qianwen Zhang,2 Qing Liu,3 Yi Du,2 Ya Jia,2 Yue-Dong He,2 Ai Zheng,2 Hui Xu,4 Shuang-Shuang Cui,5 Yong Tian,4 Lin Ran,4 Fengmei Ke4

ABSTRACT

Introduction The management of women with clinical early-stage cervical cancer and lymph node involvement detected intraoperatively is heterogeneous and controversial. This paper presents the protocol of a systematic review and meta-analysis regarding the management of this specific population of patients. This proposed study aims to answer the question: does completion of radical hysterectomy improve the oncological outcomes of women with clinical early-stage cervical cancer and intraoperatively detected nodal involvement?

Methods and analysis This protocol is drafted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols guidelines, and the proposed study will be conducted in accordance with the standard guidelines of ‘Preferred Reporting Items for Systematic Reviews and Meta-Analyses’ and ‘Meta-analysis of Observational Studies in Epidemiology reporting guideline’. Comprehensive literature searches will be performed in PubMed, Embase, Scopus, and Web of Science. The screening of the eligible studies, the extraction of data of interest, and the quality assessment of the included studies will all be independently performed by different members of our team. The primary outcome of this proposed study will be comparing the risk of recurrence or death from cervical cancer and the risk of all-cause death in patients with two different treatments (completion of radical hysterectomy or abandonment of radical hysterectomy); the secondary outcome of this proposed study will be comparing the risk of the grade 3/4 toxicities associated with the two types of management. Given the clinical heterogeneity among the included studies, data on outcomes will be pooled by random-effects models. Heterogeneity will be evaluated using the I² statistic. The risk of bias for the included studies will be evaluated using the Newcastle-Ottawa Scale or the Cochrane collaboration’s tool. The grade of evidence will be evaluated by two independent members of our team using the Grading of Recommendations, Assessment, Development and Evaluations approach.

STRENGTHS AND LIMITATIONS OF THIS STUDY

⇒ This proposed study will be the first systematic review and meta-analysis regarding this topic.
⇒ This proposed study will be conducted in strict accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.
⇒ There is a possibility of significant clinical or statistical heterogeneity among the eligible studies, the meta-analysis may not be performed.
⇒ Most of the included studies will be likely to be retrospective and observational, which will compromise the quality of the evidence.

INTRODUCTION

Worldwide, cervical cancer causes about 300,000 deaths per year.1 Because of the lack of organised screening and human papillomavirus vaccination programmes, nearly 90% of cervical cancers occur in low-income and middle-income countries.1,2 In developed countries, the incidence and associated mortality of cervical cancer have declined significantly over the past few decades.1,2

The management of cervical cancer depends largely on disease stage and locally
available resources. It might consist of surgery or chemotherapy, or a combination of both.24 For women with clinical early-stage cervical cancer, the standard treatment is radical hysterectomy and bilateral pelvic lymphadenectomy.25 One of the most controversial topics in the management algorithm for women with apparent early-stage cervical cancer is the treatment of patients with intraoperatively identified regional lymph node involvement. This dilemma was quite rare because the patients with grossly enlarged lymph nodes could be identified by preoperative imaging and were referred for definitive concurrent radiochemotherapy. With the development of sentinel lymph node mapping, however, more and more clinical early-stage cases had positive lymph nodes identified intraoperatively.9 Therefore, this topic is getting more and more attention.

According to the International Federation of Gynecology and Obstetrics (FIGO) 2018 staging system for cervical cancer, cases with regional nodal metastasis are staged as stage IIIC.3 8 Most current clinical practice guidelines do not recommend radical surgery for cervical cancer patients with positive lymph nodes.3 4 9 If nodal involvement is identified intraoperatively, abandoning radical hysterectomy is recommended.9 However, this recommendation was based mainly on low-quality evidence that was from retrospective studies with small samples.9 Therefore, the treatment of women with intraoperatively identified nodal metastasis remains controversial and inconsistent.9 10 For clinical early-stage cervical cancer patients with nodal involvement detected intraoperatively, the most important decision is whether to complete a radical hysterectomy. On one hand, radical surgery is associated with high intraoperative and postoperative morbidity of complications.11–13 On the other hand, the combination of radical hysterectomy and postoperative adjuvant radiotherapy can also increase the frequency and severity of long-term complications.14 15

What is more, the survival value of completion of radical hysterectomy for this particular population of patients is still ambiguous. Data on this topic are broadly available, but there are limited and inconsistent data for women in whom radical surgery was abandoned because of intraoperatively identified nodal metastasis.16–22

Taken together, we propose this systematic review and meta-analysis to answer this question: does completion of radical hysterectomy improve the oncological survival of women with clinical early-stage cervical cancer and intraoperatively detected nodal involvement?

METHODS AND ANALYSIS

Patient and public involvement

Due to the design of the proposed study, there will no patient and/or public get involved.

Study population

Women with clinical early-stage cervical cancer and regional lymph node metastasis that was detected intraoperatively will be the study cohort of interest. In this proposed study, clinical early-stage cervical cancer will be defined as follows: the tumour is less than 4 cm, no suspicious involvement of parametrial tissues, no suspicious involvement in the lower third of the vagina, and no signs of advanced disease. The signs of advanced disease include enlarged lymph nodes, suspected metastases of pelvic organ, or distant metastases identified by physical examination or/and preoperative imaging (ultrasound, CT or MRI).

Question of review

The oncological survival value of completion of radical hysterectomy for women with apparent early-stage cervical cancer and nodal involvement identified intraoperatively.

Study design and standards

This study will be a systematic review and meta-analysis; it will be carried out in accordance with the standard guidelines of "Preferred Reporting Items for Systematic Reviews and Meta-Analyses"23 and "Meta-analysis of Observational Studies in Epidemiology (MOOSE) reporting guidelines".24 The protocol of this study was drafted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) guidelines.25 The PRISMA-P checklist is shown in online supplemental material 1. The study protocol is registered in PROSPERO, the registration number is CRD42021273527. The planned start date of this proposed study is 1 April 2022, and the planned end date will be 1 June 2022.

Outcomes of interest

In this proposed study, we will compare the effects of the two different managements (completing or abandoning radical hysterectomy) on the oncological survival of women with clinical early-stage cervical cancer and intraoperatively identified nodal metastasis. The survival outcomes of interest in this proposed study include overall survival (OS) and disease-free survival (DFS). OS was defined as the time from the initial treatment for cervical cancer to death from any cause. DFS was defined as the time from the initial treatment for cervical cancer to disease recurrence or death from cervical cancer. Therefore, the primary outcomes of this study will be the pooled risk of recurrence or death from cervical cancer and the pooled risk of all-cause mortality. Pooled HR and 95% CI will be estimated to compare the risk of recurrence or death from cervical cancer and the risk of all-cause mortality for patients who underwent radical hysterectomy to patients who did not receive radical hysterectomy.

In this proposed study, if feasible, we will also compare the risk of the grade 3/4 toxicities of the two different managements (radical hysterectomy plus adjuvant radiochemotherapy or definitive concurrent radiochemotherapy) for women with clinical early-stage cervical cancer and intraoperatively identified nodal metastasis. The grade 3/4 toxicities were identified under the National Cancer Institute Common Terminology Criteria for Adverse Events ver.
for Adverse Events (V.5.0). Therefore, the secondary outcomes of this proposed study will be the pooled risk of the grade 3/4 toxicities. Pooled OR and 95% CI will be estimated.

Search strategy
Comprehensive literature searches will be performed in PubMed, Embase (access via OVID), Scopus, and Web of Science. We will restrict the date of publication of eligible studies to no later than 31 March 2022. Due to the limited resource and the authors’ linguistic competence, only the articles published in English will be considered for eligibility.

To ensure that the literature search will be as comprehensive as possible, the keywords for literature searches were informed by medical subject headings (MeSH), and they will be as follows: ‘cervical neoplasm’, ‘cervix neoplasm’, ‘cancer of the cervix’, ‘cervical cancer’ and ‘cervix cancer’ for disease; ‘lymph node involvement’, ‘lymph node metastasis’, ‘nodal involvement’, ‘nodal metastasis’ and ‘positive lymph node’ will be employed to further define the patient population of interest; ‘radical hysterectomy’, ‘radical surgery’, ‘radiotherapy’, ‘concurrent radiochemotherapy’, ‘radiotherapy’, ‘concurrent radiochemotherapy’, ‘chemoradiation’, ‘concurrent chemoradiation’ and ‘radiation’ for intervention. The Boolean logic (AND, OR) will be employed to combine the search terms as necessary.

Two members of our team will independently perform the literature searches, and the search strategies will be reviewed by an expert in health informatics based on the Peer Review of Electronic Search Strategies checklist. The precise search strategies for one of the databases (PubMed) are presented in online supplemental material 2. All the reference lists of the included studies will be manually checked to identify any other eligible studies that may have been omitted from the literature searches.

Study selection
All records identified from the literature searches will be entered into the EndNote reference manager (V.X9), two reviewers of our team will independently conduct the eligibility identification and any disagreement will be arbitrated by a senior reviewer. Studies will be included in this proposed systematic review and meta-analysis if they meet the following inclusion criteria: (1) enrolled adult women (18 years or older) with stage IA2 to IIA1 (based on FIGO 2009 or 2018 staging system for cervical cancer) squamous cell, adenocarcinoma, or adenosquamous carcinoma of the cervix and intraoperatively detected nodal involvement who were treated with either radical surgery followed with adjuvant radiochemotherapy (radiotherapy) or definitive concurrent radiochemotherapy (radiotherapy); (2) compared OS, DFS or progress-free survival (PFS); (3) employed a statistical method of survival analysis that was accounting for censoring and unequal follow-up among groups; (4) attempted to adjust for confounding factors known to alter survival in cancer of the cervix, such as age, comorbidity, tumour size, postoperative adjuvant therapy, whether or not underwent bilateral pelvic lymphadenectomy, the status of lymphatic vascular space invasion (LVSI), margin status, etc; (5) reported a median duration of follow-up of at least 36 months; (6) being of good quality (had a Newcastle-Ottawa Scale score of 7 points or higher) or low-risk of bias (based on the Cochrane collaboration’s tool) and (7) were reported in English. In consideration of the possibility of heterogeneity, we will allow for differences regarding the confounders included in the multivariate analysis among the eligible studies. However, only studies that at least included the following confounders will be eligible for our meta-analysis: postoperative adjuvant therapy, whether or not underwent bilateral pelvic lymphadenectomy, the status of LVSI and margin status.

Studies will be excluded from this study if their results were not reported in a peer-reviewed journal. Studies will also be excluded if they enrolled pregnant women or their study cohort was duplicated in another study. When the latter occurs, we will select the study that had a larger and more diverse sample.

Data collection
Two of us will independently extract the following data from the eligible studies using a piloted and study-specific spreadsheet: (1) the first author and the date of publication, (2) the duration and country of the study, (3) the study design, (4) the size of the sample, (5) the ethnicity of the participants, (6) the age of the participants (the mean or the median), (7) the duration of the follow-up (the mean or the median), (8) the stage of the disease (based on FIGO 2009 or 2018 staging system for cervical cancer), (9) the pathological type of the tumour, (10) the definitions of outcomes (DFS, PFS or OS), (11) the number of death and disease recurrence of the study cohort, (12) the number and the incidence of the grade 3/4 toxicities that were associated with adjuvant treatment or non-surgical definitive treatment, (13) the covariate-adjusted HRs and 95% CIs of OS, DFS or OS among patients undergoing radical hysterectomy followed with postoperative adjuvant radiochemotherapy (radiotherapy) compared with definitive concurrent radiochemotherapy (radiotherapy), (14) the covariate-adjusted ORs and 95% CIs of the grade 3/4 toxicities that were associated with adjuvant treatment or non-surgical definitive treatment, and (15) confounders that were included in the eligible studies to adjust the unbalance between patients.

The data collected will be validated by another of us to make sure integrity and accuracy. Discussion will take place among the team to solve any disagreement if necessary. If the data of interest are not available in some included studies, efforts will be made to contact the first author or the corresponding author to obtain the missing information.
Risk of bias assessment

The quality assessment for each included study will be conducted by two independent members of our team using the Newcastle-Ottawa Scale (non-randomised studies) or the Cochrane collaboration’s tool (randomised clinical studies). Any disagreement during this process will be resolved by discussion. The Newcastle-Ottawa Scale assesses study bias based on the following three domains: (1) the selection of participants, (2) the measures of exposure and outcome variables, and (3) the control of confounding. The scale concludes with a quantitative summary score and qualitative categorisation of quality (high, moderate or low) according to the number of points in the three aspects. As is accepted in the published literature, the quality of a study is considered high if the Newcastle-Ottawa Scale score is 7 or greater. The Cochrane collaboration’s tool evaluates the quality of included studies in the following six key domains: (1) selection bias (random sequence generation and allocation concealment), (2) performance bias (blinding of participants and personnel), (3) detection bias (blinding of outcome assessment), (4) attrition bias (incomplete outcome data), (5) reporting bias (selective reporting), and (6) other bias. A study is judged to be of ‘low-risk’ of bias if the risk of bias for all the six key domains is low.

If 10 or more studies will be included in this proposed meta-analysis, the publication bias will be assessed using the visual inspection of the funnel plot and the statistical analysis of the Egger test. The trim and fill method will be employed to detect and correct for funnel plot asymmetry arising from publication bias, if necessary.

Data analysis

In consideration of the clinical heterogeneity among the included studies, data on outcomes will be pooled by random-effects models. Clinical heterogeneity among the included studies includes, but is not limited to, the following: duration of follow-up, inclusion criteria, disease stage of the tumour, age of the sample and protocol for the adjuvant/definitive radiochemotherapy. Statistical heterogeneity among the eligible studies will be evaluated using the $I^2$ statistic and $F$ values of less than 25%, between 25% and 50%, and greater than 50% are considered low, moderate, and high heterogeneity, respectively. Pooled HRs and 95% CIs will be estimated to compare the risk of disease recurrence or death and the risk of all-cause mortality or cancer-associated death for patients treated with radical hysterectomy and adjuvant therapies relative to definitive non-surgical therapies. Pooled ORs and 95% CIs will also be estimated to compare the risk of the grade 3/4 toxicities of the two types of management.

Many sensitivity analyses will be employed to evaluate the robustness of the main results. To check whether any study has a disproportionate influence on the results of the meta-analysis, data will be synthesised after serially excluding each study included in the main analysis. To evaluate whether the results are sensitive to the employment of the meta-analysis model, a fixed-effects meta-analysis will be conducted.

Grading of evidence

The grade of the evidence will be evaluated according to the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. Two researchers will independently evaluate the grade of evidence of this proposed study; a third researcher will be consulted in case of disagreements.

DISCUSSION

For the management of clinical early-stage cervical cancer patients who had intraoperatively identified nodal involvement, current clinical practices are heterogeneous and not based on strong evidence. Thus, this proposed systematic review and meta-analysis is of high clinical significance. By pooling the data of the original high-quality studies regarding this topic, this proposed study can provide gynaecological oncologists with the current best estimates of the prognostic value of different management modalities for clinical early-stage cervical cancer patients who had intraoperatively identified nodal involvement, and can assist consultation and shared decision making.

As far as we know, the largest study to date regarding this topic is the ABRAX (ABandoning RAdical hysterectomy in cervix cancer) study. The ABRAX study was an international, multicentre, retrospective cohort study, and the ABRAX consortium was composed of 51 institutions across 19 countries in Europe, Central America and Latin America and was led by the Central and Eastern European Gynecologic Oncology Group (CEEGOG). The ABRAX study enrolled 515 cervical cancer in whom nodal metastasis was identified intraoperatively, of which 361 underwent the planned uterine surgery, and the rest gave up surgical treatment. The ABRAX study did not find significant difference regarding the risks of recurrence (HR 1.154, 95% CI 0.799 to 1.666, p=0.45), pelvic recurrence (HR 0.836, 95% CI 0.458 to 1.523, p=0.56) or death (HR 1.064, 95% CI 0.690 to 1.641, p=0.78) between the two groups. Thus, the authors concluded that completion of radical hysterectomy does not improve survival in patients with intraoperatively detected nodal involvement. Of note, there were some limitations. The first was its retrospective design, so there was inevitably some bias. The second was that it did not evaluate the risk of morbidity and mortality associated with the two types of treatment protocol. The last, the ABRAX did not address the prognostic role of pelvic lymphadenectomy for the clinical early-stage cervical cancer patients who had intraoperatively identified nodal involvement.

This proposed systematic review and meta-analysis may have the following limitations. In consideration of the fact that prospective study regarding this topic in the practical clinical setting is very unlikely, we guess that the majority of the included studies will also be retrospective design;
this will compromise the grade of evidence concluded from this proposed study. Also, there is the possibility that substantial heterogeneity exists among the eligible studies, which will make meta-analysis impossible.

**Author affiliations**

1Department of Obstetrics and Gynecology, Mianzhu City People’s Hospital, Mianzhu, Sichuan, China
2Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China
3Department of Obstetrics and Gynecology, Reproductive & Women-Children Hospital, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China
4Department of Obstetrics and Gynecology, Enshi Clinical College of Wuhan University, Enshi, Hubei, China
5Department of Obstetrics and Gynecology, Jianshi Hospital of Chinese Medicine, JianShi, Hubei, China

**Contributors**

CH, YX, YD and QL conceived the review topic. YX and YD performed background exploratory searches and drafted the initial search strategy. CH, YX, YD and YJ co-wrote the initial protocol. QZ, YDHI and AZ provided critical appraisal and senior oversight of the protocol. For the systematic review, CH, YX, YD, HY, YT, LR, FK, SSC and YJ will perform the searches, data extraction and analysis. AZ and YDHI will provide oversight of the searches, data analysis and extraction. QZ, YDH, YT, LR, FK, SSC and AZ will provide critical appraisal and senior oversight of the final manuscript.

**Funding**

The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests**

None declared.

**Patient and public involvement**

Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication**

Not applicable.

**Provenance and peer review**

Not commissioned; externally peer reviewed.

**Supplemental material**

This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been vetted by SGO members.

**Open access**

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID iDs**

Yu Xu http://orcid.org/0000-0001-9819-1965
Qianwen Zhang http://orcid.org/0000-0002-9578-1334
Ai Zheng http://orcid.org/0000-0002-3403-9101
Yong Tian http://orcid.org/0000-0002-7625-1589
Fengmei Ke http://orcid.org/0000-0001-9318-2381

**REFERENCES**

1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7–30.
2 Cohen PA, Jhingran A, Oaknin A, et al. Cervical cancer. Lancet 2019;393:169–82
3 Abu-Rustum NR, Yashar CM, Bean S, et al. NCCN guidelines insights: cervical cancer, version 1.2020. J Natl Compr Canc Netw 2020;18:860–6.
4 Martc C, Landoni F, Mahner S, et al. Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017:28:x72–83.
5 Hill EK. Updates in cervical cancer treatment. Clin Obstet Gynecol 2020;63:3–11.
6 Cibula D, McCluggage WG. Sentinel lymph node (SLN) concept in cervical cancer: current limitations and unanswered questions. Gynecol Oncol 2019;152:202–7.
7 Wright JD, Matsuo K, Huang Y, et al. Prognostic performance of the 2018 International Federation of Gynecology and Obstetrics cervical cancer staging guidelines. Obstet Gynecol 2019;134:49–57.
8 Matsuo K, Machida H, Mandelbaum RS, et al. Validation of the 2018 FIGO cervical cancer staging system. Gynecol Oncol 2019;152:87–93.
9 Cibula D, Pöpper R, Planchamp F, et al. The European Society of Gynaecological Oncology/European Society for radiotherapy and Oncology/European Society of pathology guidelines for the management of patients with cervical cancer. Radiother Oncol 2018;127:404–16.
10 Garg G, Shah JP, Toy EP, et al. Intra-Operative detection of nodal metastasis in early stage cervical cancer: a survey of the practice patterns of SGO members. Gynecol Oncol 2011;121:143–7.
11 Le Borgne G, Mercier M, Woronoff A-S, et al. Quality of life in long-term cervical cancer survivors: a population-based study. Gynecol Oncol 2013;129:222–8.
12 Hwang JH. Urologic complication in laparoscopic radical hysterectomy: meta-analysis of 20 studies. Eur J Cancer 2012;48:3177–85.
13 Oman SA, Schwartz D, Muntz HG. Lower limb compartment syndrome as a complication of radical hysterectomy. Gynecol Oncol Rep 2016;16:39–41.
14 Rotman M, Sedlis A, Piedmonte MR, et al. A phase III randomized trial of postoperative pelvic irradiation in stage Ib cervical carcinoma with poor prognostic features: follow-up of a gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys 2006;65:169–76.
15 Ryan M, Stainton MC, Slayter EK, et al. Aetiologie and prevalence of lower limb lymphoedema following treatment for gynaecological cancer. Aust N Z J Obstet Gynaecol 2009;39:79–84.
16 Cibula D, Abu-Rustum NR, Duske L, et al. Prognostic significance of low volume sentinel lymph node disease in early-stage cervical cancer. Gynecol Oncol 2012;124:496–501.
17 Richard SD, Krivak TC, Castleberry A, et al. Survival for stage IB cervical cancer with positive lymph node involvement: a comparison of completed vs. abandoned radical hysterectomy. Gynecol Oncol 2008;109:43–8.
18 Potter ME, Alvarez RD, Shingleton HM, et al. Early invasive cervical cancer with pelvic lymph node involvement: to complete or not to complete radical hysterectomy? Gynecol Oncol 1990;37:78–81.
19 Suprasert P, Srisomboon J, Charoenkwan K, et al. Outcomes of abandoned radical hysterectomy in patients with stages IB-IIA cervical cancer found to have positive nodes during the operation. Int J Gynaecol Cancer 2006;15:498–502.
20 Whitney CW, Stehman FB. The abandoned radical hysterectomy: a gynecologic Oncology Group study. Gynecol Oncol 2000;79:350–6.
21 Ziebarth AJ, Smith H, Killian ME, et al. Completed versus aborted radical hysterectomy for node-positive stage Ib cervical cancer in the modern era of chemoradiation therapy. Gynecol Oncol 2012;126:69–72.
22 Dostalek L, Runnebaum I, Raspagliesi F, et al. Oncologic outcome after completing or abandoning (radical) hysterectomy in patients with cervical cancer and intraoperative detection of lymph node positivity: ABRAX (abandoning Rad hyst in cervix cancer). Int J Gynaecol Cancer 2020;30:261–4.
23 Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.
24 Group DF, Berlin JA, Morton SC, et al. Meta-Analysis of observational studies in epidemiology: a proposal for reporting, meta-analysis of observational studies in epidemiology (moose) group. JAMA 2000;283:2008–12.
25 Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2016;354:i4086.
26 Freites-Martinez A, Santana N, Arias-Santiago S, et al. Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies. Actas Dermosifiliogr 2021;112:90–2.
27 McGowan J, Sampson M, Salzwedel DM, et al. PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. J Clin Epidemiol 2016;75:40–6.
28 Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603–5.
29 Higgins JPT, Altman DG, Getzschke PC, et al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
30 Houghton JSM, Nickinson ATO, Morton AJ, et al. Frailty factors and outcomes in vascular surgery patients: a systematic review and meta-analysis. Ann Surg 2020;272:266–76.
31 Zhang T, Sidorchuk A, Sevilla-Cermeno L, et al. Association of cesarean delivery with risk of neurodevelopmental and psychiatric disorders in the offspring: a systematic review and meta-analysis. JAMA Netw Open 2019;2:e1910236.
32 Mohammed SH, Habtewold TD, Birhanu MM, et al. Neighbourhood socioeconomic status and overweight/obesity: a systematic review and meta-analysis of epidemiological studies. BMJ Open 2019;9:e028238.
33 Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.
34 Knoll T, Omar MI, Maclean S, et al. Key steps in conducting systematic reviews for underpinning clinical practice guidelines: methodology of the European association of urology. Eur Urol 2018;73:290–300.
35 DerSimonian R, Laird N. Meta-Analysis in clinical trials. Control Clin Trials 1986;7:177–88.
36 DerSimonian R, Laird N. Meta-Analysis in clinical trials revisited. Contemp Clin Trials 2015;45:139–45.
37 Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557–60.
38 Iorio A, Spencer FA, Falavigna M, et al. Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. BMJ 2015;350:h870.
39 Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924–6.
40 Cibula D, Dostalek L, Hillemanns P, et al. Completion of radical hysterectomy does not improve survival of patients with cervical cancer and intraoperatively detected lymph node involvement: ABRAX international retrospective cohort study. Eur J Cancer 2021;143:88–100.
Supplementary material 1. PRISMA-P-checklist

| Section and topic | Item No | Checklist item |
|-------------------|---------|----------------|
| **ADMINISTRATIVE INFORMATION** | | |
| Title: | | |
| Identification | 1a | Identify the report as a protocol of a systematic review | Page 1 |
| Update | 1b | If the protocol is for an update of a previous systematic review, identify as such | N/A |
| Registration | 2 | If registered, provide the name of the registry (such as PROSPERO) and registration number | not available at present |
| Authors: | | |
| Contact | 3a | Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author | Page 1 |
| Contributions | 3b | Describe contributions of protocol authors and identify the guarantor of the review | Page 11 |
| Amendments | 4 | If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments | N/A |
| Support: | | |
| Sources | 5a | Indicate sources of financial or other support for the review | Page 11 |
| Sponsor | 5b | Provide name for the review funder and/or sponsor | Page 11 |
| Role of sponsor or funder | 5c | Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol | Page 11 |
| **INTRODUCTION** | | |
| Rationale | 6 | Describe the rationale for the review in the context of what is already known | Page 3-4 |
| Objectives | 7 | Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO) | Page 3-4 |
| **METHODS** | | |
| Eligibility criteria | 8 | Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review | Page 7 |
| Information sources | 9 | Describe all intended information sources (such as electronic databases, contact with study authors, trial registries or other grey literature sources) with planned dates of coverage | Page 6 |
| Search strategy | 10 | Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated included as a supplementary file | |
| Study records: | | |
| Data management | 11a | Describe the mechanism(s) that will be used to manage records and data throughout the review | Page 6-7 |
| Component | Code | Description |
|-----------|------|-------------|
| Selection process | 11b | State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis) Page 6-7 |
| Data collection process | 11c | Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators Page 6-7 |
| Data items | 12 | List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications Page 6-7 |
| Outcomes and prioritization | 13 | List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale Page 5-6 |
| Risk of bias in individual studies | 14 | Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis Page 8 |
| Data synthesis | 15a | Describe criteria under which study data will be quantitatively synthesised Page 9 |
| | 15b | If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I², Kendall’s τ) Page 9 |
| | 15c | Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression) Page 9 |
| | 15d | If quantitative synthesis is not appropriate, describe the type of summary planned Page 9 |
| Meta-bias(es) | 16 | Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies) Page 9 |
| Confidence in cumulative evidence | 17 | Describe how the strength of the body of evidence will be assessed (such as GRADE) Page 9 |

*It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L. PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.
The precise search strategies

For PubMed

#1  (((cervical neoplasm>Title/Abstract]) OR (cervix neoplasm>Title/Abstract]) OR (cancer of the cervix>Title/Abstract]) OR (cervical cancer>Title/Abstract]) OR (cervix cancer>Title/Abstract])
#2  (((lymph node involvement>Title/Abstract]) OR (lymph node metastasis>Title/Abstract]) OR (nodal involvement>Title/Abstract]) OR (nodal metastasis>Title/Abstract]) OR (positive lymph node>Title/Abstract])
#3  (((((((radical hysterectomy>Title/Abstract]) OR (radical surgery>Title/Abstract]) OR (definitive radiochemotherapy>Title/Abstract]) OR (radical radiotherapy>Title/Abstract]) OR (concurrent radiochemotherapy>Title/Abstract]) OR (definitive chemoradiation>Title/Abstract]) OR (concurrent chemoradiation>Title/Abstract]) OR (radical radiation>Title/Abstract])
#4  #1 AND #2 AND #3

For Web of Science

#1  cervical neoplasm (Topic) or cervix neoplasm (Topic) or cancer of the cervix (Topic) or cervical cancer (Topic) or cervix cancer (Topic)
#2  lymph node involvement (Topic) or lymph node metastasis (Topic) or nodal involvement (Topic) or nodal metastasis (Topic) or positive lymph node (Topic)
#3  radical hysterectomy (Topic) or radical surgery (Topic) or definitive radiochemotherapy (Topic) or radical radiotherapy (Topic) or concurrent radiochemotherapy (Topic) or definitive chemoradiation (Topic) or concurrent chemoradiation (Topic) or radical radiation (Topic)
#4  #1 AND #2 AND #3

For Embase

#1  'cervical neoplasm':ab,ti or 'cervix neoplasm':ab,ti or 'cancer of the cervix':ab,ti or 'cervical cancer':ab,ti or 'cervix cancer':ab,ti
#2  'lymph node involvement':ab,ti or 'lymph node metastasis':ab,ti or 'nodal involvement':ab,ti or 'nodal metastasis':ab,ti or 'positive lymph node':ab,ti
#3  'radical hysterectomy':ab,ti OR 'radical surgery':ab,ti OR 'definitive radiochemotherapy':ab,ti OR
'radical radiotherapy':ab,ti OR 'concurrent radiochemotherapy':ab,ti OR 'definitive chemoradiation':ab,ti OR 'concurrent chemoradiation':ab,ti OR 'uterine serous carcinoma':ab,ti OR 'radical radiation':ab,ti

#4  #1 AND #2 AND #3